Acute Rhinosinusitis In Children Research Articles

Topical antibiotics for acute rhinosinusitis in children

In this article, the authors provide an overview of existing data on the use of topical antibacterial drugs in acute rhinosinusitis in children. General information on the etiology of acute rhinosinusitis is given. Indications for systemic and topical antibiotic therapy in acute rhinosinusitis are noted, indicated in Russian and international consensus documents. The advantages of using the combined preparation of thiamphenicol and N-acetylcysteine in acute rhinosinusitis in children and adults are considered separately. It is concluded that the topical antibacterial therapy of acute rhinosinusitis, despite all its advantages, is not an equivalent substitute for systemic antibacterial therapy in the treatment of severe and, especially, complicated forms of acute rhinosinusitis. The practitioner should be guided by the indications for systemic and topical antibacterial therapy adopted in Russian consensus documents. If there are indications for systemic antibiotic therapy, local remedies are only ancillary treatment, the action of which is aimed at enhancing the effect of systemic antibiotics. In the case of monotherapy with local drugs containing antibacterial components, it is mandatory to re-evaluate the patient’s condition and the dynamics of the symptoms of the disease for 2–3 days of treatment, and in the absence of positive changes, reconsider the need for systemic antibacterial therapy. More promising is the use of combined drugs that, in addition to affecting the causative agent of the disease, achieve anti-inflammatory, decongestion or mucolytic effects. It is convenient and rational to use nasal sprays, however, in order to improve the delivery of the active substance to the site of inflammation in acute rhinosinusitis, the use of nebulizer is justified.

Nasal cavity care in newborns and young children with rhinitis: current trends

The article describes the features of the structure and functioning of the nasal mucosa in newborns and young children. The remarkable thing is that the nasal cavity and paranasal sinuses serve as a particular air conditioner that provides almost 100% hydration, heating, filtering and catchment of foreign particles. The development of pathology and functional disorders in the newborns and young children have serious consequences, such as respiratory distress or discomfort, sleep cycle disorder, an increased risk of obstructive sleep apnea and difficulties with feeding. The authors analysed the role and efficacy of nasal irrigation taking into account the solution concentration and the type of irrigation device, and reported the effect of elimination-irrigation therapy on mucociliary clearance and trophic epithelium of the nasal mucosa. It has been proved that the standard treatment (antibiotics, mucolytics and local nasal decongestants) for acute rhinosinusitis in children is more effective, if the treatment protocol includes irrigation of the nasal cavity with isotonic solution, and not without adverse events, in contrast to decongestants, which use increases the risk for tachyphylaxis. The authors determined the role of irrigation and elimination therapy in the prevention of pathology of the nasal cavity and paranasal sinuses and in the complex therapy for acute and exacerbation of chronic rhinosinusitis in newborns and young children. The most common mistakes in caring for the nasal cavity in newborns and young children are highlighted. The article identifies the main indications for the use of Otrivin Baby aspirator and drops, and clarifies the main positions for using Otrivin Baby aspirator. It also describes the advantages of using Otrivin Baby device, which includes an aspirator and sterile isotonic solution drops for safe and effective care for the nasal cavity in newborns and young children with rhinitis.

Serious complications due to acute rhinosinusitis in children up to five years old in Stockholm, Sweden – Still a challenge in the pneumococcal conjugate vaccine era

ObjectivesThe aim of this study was to analyze the rate of admissions, the rate of serious complications (postseptal orbital complications and surgery) and the bacterial etiology of acute rhinosinusitis in hospitalized children under five years old in Stockholm County, eight years after the introduction of the pneumococcal conjugate vaccine (PCV). The secondary aim was to compare this period with the period four years prior to the vaccine's introduction. MethodsThis was a population-based, descriptive observational study with retrospectively collected data from 1 July 2008 to 30 June 2016 in Stockholm County. Hospital admissions of children with a discharge diagnosis of rhinosinusitis and related complications were reviewed and compared to the pre-PCV period of 2003–2007. ResultsA total of 215 children were admitted, for a yearly incidence of 18.8 per 100 000 children (22.8 for boys, 14.6 for girls). Computer tomography-verified postseptal orbital complications occurred in 29 cases (13.5%) and surgery was necessary in nine (4.2%). Pathogens other than Streptococcus pneumoniae were found in the cases with postseptal complication or surgery (Streptococcus pyogenes in four, Haemophilus influenzae in three and Staphylococcus aureus in one case). In comparison to the four years pre-PCV, the incidence of admission decreased from 43.81 to 20.31 and 17.45 per 100 000/year for the two four-year periods after vaccine introduction. The incidence of CT-verified postseptal complication increased slightly from 1.51 to 2.34 and 2.74 per 100 000/year. The incidence of surgeries increased marginally but continued to be very low, from 0.22 to 0.54 and 1.03 per 100 000/year. ConclusionsComplications due to acute rhinosinusitis in children living in Stockholm County continues to be very rare after the introduction of pneumococcal vaccine. Hospitalization has decreased for children under five years old after PCV introduction, but the incidence or postseptal complications and surgery in the same population increased slightly. Predominantly bacteria other than Streptococcus pneumoniae was found. There is a need of larger studies to determine trends, and a need of prospective studies to elucidate the bacterial etiology, of serious complications due to acute rhinosinusitis in children.

Efficacy of combined treatment of acute rhinosinusitis in children

The article presents the results of the study of clinical efficacy of treatment of acute rhinosinusitis in 80 children aged 3–15 years using Sialor® as an adjunct to comprehensive treatment. The children of group 1 (active treatment group) received Sialor® in addition to the standard treatment without use of decongestants. group 2 (comparison group) received decongestants in addition to the standard treatment without use of Sialor®. The efficacy of treatment was assessed according to clinical examination findings. The study showed that the inclusion of Sialor® (silver proteinate) in the combined treatment improves the clinical efficacy of treatment of acute rhinosinusitis. On Day 4 after the first examination, group I showed a decrease in nasal congestion that was evaluated using Visual Analogue Scale (VAS) by more than 4 points as compared with group 2. On Day 4 of treatment, presentations of rhinorrhea in the active treatment group of children decreased by more than 2 points on VAS scale compared with the control group. The children who received Sialor also demonstrated an improvement in the quality of sleep. The results showed that the inclusion of Sialor (silver proteinate) in the treatment regimen of ARS allows to achieve a more rapid relief of symptoms of intoxication, nasal congestion, rhinorrhea, restoration of smell, improvement in the quality of sleep of patients by Day 4 from the start of treatment.

Could seasonal allergy be a risk factor for acute rhinosinusitis in children?

To evaluate the incidence of acute rhinosinusitis in children with grass pollen induced rhinitis during the period of grass pollinosis. Children with nasal symptoms from grass pollen induced rhinitis but without rhinosinusitis symptoms were selected. Their parents were asked to complete a diary during pollen exposure to report nasal symptoms and drugs used daily. When rhinosinusitis was suspected, the confirmatory diagnosis of acute rhinosinusitis was made by fibro-endoscopy. Children without inhalant allergy served as controls. Seventeen out of 242 children (7.0 per cent) had a diagnosis of acute rhinosinusitis, confirmed by fibro-endoscopy, during grass pollination, compared to 3 out of 65 (4.6 per cent) in the control group (p = 0.49). Among allergic children, those with acute rhinosinusitis had symptoms for a greater number of days and/or a higher symptoms score than children without acute rhinosinusitis. Children with grass pollen induced rhinitis during exposure to pollen have an incidence of endoscopically confirmed acute rhinosinusitis comparable to non-allergic children. This suggests that grass pollen induced rhinitis is a negligible risk factor for acute rhinosinusitis.

Orbital complications of acute rhinosinusitis in children: a retrospective review of 33 patients

Orbital complications of acute rhinosinusitis in children: a retrospective review of 33 patients

Diagnosis and treatment of acute rhinosinusitis in children

Diagnosis and treatment of acute rhinosinusitis in children

Treatment of Orbital Complications Following Acute Rhinosinusitis in Children.

The orbital complications account for about 80% of all complications secondary to acute rhinosinusitis. If the treatment is not correct and in time, orbital complications could progress rapidly, leading to optic neuritis, cavernous sinus thrombophlebitis or life-threatening intracranial complications. To evaluate the therapeutic efficacy of conservative therapy for the patients with orbital cellulitis and endoscopic sinus surgery (ESS) performed on patients with subperiosteal abscess (SPA) secondary to acute rhinosinusitis in children. Retrospective cross-sectional study. The retrospective study included 31 pediatric patients with orbital complications secondary to acute rhinosinusitis. In all cases, intensive treatment was initiated with a combination of oral or intravenous antibiotics, glucocorticoid and gelomyrtol forte after admission. ESS was performed if an improvement in the condition of patients did not occur after 48 hours. However, the patients with orbital SPA, motility disorders of eyeball or decreased vision received ESS immediately within 24 hours. Sixteen patients were cured by conservative therapy and 15 patients by ESS. All of the signs and symptoms disappeared after conservative therapy or ESS. There were no recurrences within the follow-up period of 1 to 8 years. Conservative therapy is an effective method for patients with inflammatory edema and most cases of orbital cellulitis in children. SPA can be cured by ESS.

EVALUATION OF THE CLINICAL EFFICACY OF A PHYTOTHERAPEUTIC DRUG IN THE TREATMENT AND PREVENTION OF RECURRING ACUTE RHINOSINUSITIS IN CHILDREN OF CHELYABINSK

The article presents the results of own study of clinical efficacy of myrtol standardized in the treatment of relapses of acute rhinosinusitis in children. The study included patients with acute rhinosinusitis confirmed clinically and instrumentally. The comparative open study using clinical, laboratory, biochemical, immunological and statistical methods was conducted in January – March and September – November 2015. 73 patients (mean age – 9,5 ± 3) were examined and treated. In group 1 (nasal irrigation by Proetz), improvement in patients according to the VAS was achieved on day 4 of disease. In group 2 (receiving GeloMyrtol®), improvement was observed on day 3 of disease. The period of recovery in group 1 was more than 8 days, in group 2 – less than 6–7 days.

Use of Myrtol standardized in the treatment of children with acute rhinosinusitis

The present study included 60 children at the age from 6 to 10 years undergoing a course of out-patient and in-patient treatment of acute rhinosinusitis (ARS). Thirty of these patients were given Myrtol standardised in the dose of 120 mg thrice daily for 7 days, in addition to traditional therapy.With convincing objective data for acute bacterial rhinosinusitis (in accordance with the criteria of EP3OS 2012), antibacterial preparations were prescribed to the children. The remaining patients received either conventional (symptomatic, irrigation) therapy or systemic antimicrobial agents. The analysis of characteristics of the visual-analog scale reflecting the severity of rhinorrhea, basal congestion, and coughing has demonstrated a significant (р<0,05) difference between the two groups of children in terms of manifestations of the clinical symptoms within days 7 and 14 after the onset of the treatment. For basal congestion, the difference was apparent as soon as day 3 after the beginning of therapy. The duration of the treatment with intranasal vasoconstrictive medications used for symptomatic therapy by the patients given Myrtol standardized was 2.2±0.4 days in comparison with 3.6±0.5 days in the control group. None of the patients treated with GeloMyrtol exhibited any adverse reaction attributable to the action of the medication in being studied. The study has demonstrated that using Myrtol standardized for the treatment of the uncomplicated forms of acute rhinosinusitis in children is clinically effective, safe, and convenient method for the management of ARS in children. And it can be recommended for the wide practical application.

Clinical Consideration of Isolated Bacteria in Nasal Discharge Associated with Acute Rhinosinusitis in Children at the Intermountain Medical Region

Clinical Consideration of Isolated Bacteria in Nasal Discharge Associated with Acute Rhinosinusitis in Children at the Intermountain Medical Region

Clinical characteristics of recurrent acute rhinosinusitis in children.

Recurrent acute rhinosinusitis (RARS) is defined as multiple episodes of acute rhinosinusitis in which the symptoms and signs of infection resolve completely between episodes. Limited data are available on the characteristics and preventive therapy of RARS. This study evaluated the clinical characteristics and predisposing factors of RARS in children as well as the preventive therapy. Medical records of children with RARS diagnosed between January 2010 and December 2012 were obtained. Demographic data, presenting symptoms, predisposing factors and preventive therapy were reviewed. Ninety-four children with RARS were recruited. The mean age was 7.7±2.6 years, with a mean age of onset of 4.0±1.4 years. Sixty-one patients (64.9%) were boys and 56 patients (59.6%) had family history of atopy. The most common presenting symptom of RARS was purulent nasal discharge (100.0%), followed by nasal congestion (68.1%) and postnasal drainage (31.9%). The most common predisposing factor for RARS was immunoglobulin G subclass deficiency (78.7%), followed by non-allergic rhinitis (64.9%) and allergic rhinitis (35.1%). Sixty-five children (69.1%) received preventive therapy for RARS. The responses to preventive measures were: 80.0% (32/40 patients) to oral antibiotic prophylaxis, 50.0% (11/22 patients) to adenotonsillectomy, 91.7% (11/12 patients) to specific allergen immunotherapy, 27.3% (3/11 patients) to gentamicin nasal irrigation, and 66.7% (4/6 patients) to intravenous immunoglobulin. The most common presenting symptoms of RARS in children were purulent nasal discharge, nasal congestion and postnasal drainage. Children with RARS should be evaluated for the presence of underlying conditions such as immunodeficiency and allergic disease, which led to the appropriate management for these children.

Nasal saline irrigation with or without systemic antibiotics in treatment of children with acute rhinosinusitis

ObjectivesAcute rhinosinusitis (ARS) is a common pediatric problem. Our aim was to determine the efficacy of normal nasal saline irrigation (NSI) with or without amoxicillin in treatment of acute rhinosinusitis (ARS) in children. MethodsIt is a prospective randomized, blind placebo-controlled trial. Children with uncomplicated ARS were recruited. One group received (amoxacillin 100mg/kg/day) and 0.9% NSI. The second group received placebo and 0.9% NSI. The primary outcome was the effect of treatment on clinical response. Secondary outcomes included: Rating of Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ), middle meatus (MM) bacteriological and cytological cellular responses and adverse effects. ResultsSixty two patients with ARS were eligible for the study. In amoxicillin group (31 patients); clinical cure was observed in 26 (83.9%) in comparison to 22 (71%) patients in NSI without antibiotics group (31 patients) (p=0.22). No differences between both groups in the reported nasal symptom scores and total symptoms scores improvements at day 7 (p=0.09 and 0.65) and day 14 (p=0.29 and 0.14), respectively. The mean total PRQLQ values had no differences between both groups after the 2 weeks of treatment (p=0.06). At day 7, MM neutrophils reduced significantly in amoxicillin group in comparison to placebo group (p=0.004). At day 14, the MM cytological content had no differences between both groups (p=0.07). Normal NSI with placebo has less reported adverse effects than amoxicillin and nasal saline irrigations (p=0.005). ConclusionsNSI can be used alone with the same clinical, bacteriological and cytological cellular changes efficacy and with higher safety profile than amoxicillin after 14 days of treatment in uncomplicated clinically diagnosed ARS in children.

Современные особенности течения острого риносинусита у детей

Современные особенности течения острого риносинусита у детей

山間地域医療圏における小児急性鼻副鼻腔炎よりの鼻汁検出菌の検討

山間地域医療圏における小児急性鼻副鼻腔炎よりの鼻汁検出菌の検討

Diseases of the nose and paranasal sinuses in child.

Diseases of the pediatric nose and nasal sinuses as well as neighboring anatomical structures encompass a variety of pathologies, especially of inflammatory nature. Congenital disease, such as malformations and structural deviations of the nasal septum, as well as systemic metabolic pathologies affecting the nose and sinuses, rarely require medical therapy from an Otolaryngologist. The immunological function of the mucosa and genetic factors play a role in the development of disease in the pediatric upper airway tract, especially due to the constantly changing anatomy in this growth phase. Disease description of the nose and nasal sinuses due to mid-facial growth must also take developmental age differences (infant, toddler, preschool, and school age) into account. Epidemiological examinations and evidence based studies are often lacking in the pediatric population.The wide range of inflammatory diseases of the nose and paranasal sinuses, such as the acute and chronic rhinosinusitis, the allergic rhinitis, and adenoid disease, play a role in the susceptibility of a child to infection. The susceptibility to infection depends on the pediatric age structure (infant, young child) and has yet to be well defined. The acute rhinosinusitis in children develops after a viral infection of the upper airways, also referred to as the “common cold” in the literature. It usually spontaneously heals within ten days without any medical therapy. Antibiotic therapy is prudent in complicated episodes of ARS. The antibiotic therapy is reserved for children with complications or associated disease, such as bronchial asthma and/or chronic bronchitis. A chronic rhinosinusitis is defined as the inflammatory change in the nasal mucosa and nasal sinus mucosa, in which the corresponding symptoms persist for over 12 weeks. The indication for CT-imaging of the nasal sinuses is reserved for cases of chronic rhinosinusitis that have been successfully treated with medication. A staged therapeutic concept is followed in CRS based on conservative and surgical methods. Nasal sinus surgery is considered nowadays as effective and safe in children. Based on the assumption that adenoids are a reservoir for bacteria, from which recurrent infections of the nose and nasal sinus originate, the adenoidectomy is still defined as a cleansing procedure in rhinosinusitis. 69.3% of the children had benefit from adenoidectomy. Comorbidities, such as pediatric bronchial asthma, presently play an even more important role in the therapy of rhinosinusitis; therefore, it is often wise to have the support of pediatricians. In western European countries 40% of children presently suffer from allergic rhinitis, in which pronounced nasal obstruction can cause disturbed growth in facial bones. An early therapy with SIT may prevent the development of bronchial asthma and secondary sensitization to other allergens. Therefore, SIT is recommended in treatment of allergic rhinitis whenever, if possible. The assessment of diagnostic tools is for the examiner not often possible due to the lack of evidence. Rhinosurgical approaches are often described in study reports; however, they lack the standard prospective randomized long-term study design required nowadays and can only be evaluated with caution in the literature.

HERBAL DRUGS IN PEDIATRIC RHINOSINUSITS TREATMENT

The article referred to the use of herbal drugs in treatment of acute rhinosinusitis in children. Topical aspects of the etiology, pathogenesis, clinical manifestations and diagnosis of acute rhinosinusitis in children are disscussed. The advantages of application of herbal drugs in such pathology are discussed indications for these drugs and possible side effects. The results of research of the efficacy and safety of herbal drugs for the treatment and prevention of acute sinusitis in children are adduced .

Erkrankungen der Nase und der Nasennebenhöhlen im Kindesalter

Diseases of the pediatric nose and paranasal sinuses as well as neighboring anatomical structures encompass a variety of pathologies, especially of inflammatory nature. Congenital disease, such as malformations and structural deviations of the nasal septum, as well as systemic metabolic pathologies affecting the nose and sinuses, rarely require medical therapy from an Otolaryngologist. The immunological function of the mucosa and genetic factors play a role in the development of disease in the pediatric upper airway tract, especially due to the constantly changing anatomy in this growth phase. Disease description of the nose and nasal sinuses due to mid-facial growth must also take developmental age differences (infant, toddler, preschool, and school age) into account. Epidemiological examinations and evidence based studies are often lacking in the pediatric population. The wide range of inflammatory diseases of the nose and paranasal sinuses, such as the acute and chronic rhinosinusitis, the allergic rhinitis, and adenoid disease, play a role in the susceptibility of a child to infection. The susceptibility to infection depends on the pediatric age structure (infant, young child) and has yet to be well defined. The acute rhinosinusitis in children develops after a viral infection of the upper airways, also referred to as the "common cold" in the literature. It usually spontaneously heals within ten days without any medical therapy. Antibiotic therapy is prudent in complicated episodes of ARS. The antibiotic therapy is reserved for children with complications or associated disease, such as bronchial asthma and/or chronic bronchitis. A chronic rhinosinusitis is defined as the inflammatory change in the nasal mucosa and nasal sinus mucosa, in which the corresponding symptoms persist for over 12 weeks. The indication for CT-imaging of the nasal sinuses is reserved for cases of chronic rhinosinusitis that have been successfully treated with medication. A staged therapeutic concept is followed in CRS based on conservative and surgical methods. Nasal sinus surgery is considered nowadays as effective and safe in children. Based on the assumption that adenoids are a reservoir for bacteria, from which recurrent infections of the nose and nasal sinus originate, the adenoidectomy is still defined as a cleansing procedure in rhinosinusitis. 69.3% of the children had benefit from adenoidectomy. Comorbidities, such as pediatric bronchial asthma, presently play an even more important role in the therapy of rhinosinusitis; therefore, it is often wise to have the support of pediatricians. In western European countries 40% of children presently suffer from allergic rhinitis, in which pronounced nasal obstruction can cause disturbed growth in facial bones. An early therapy with SIT may prevent the development of bronchial asthma and secondary sensitization to other allergens. Therefore, SIT is recommended in treatment of allergic rhinitis whenever, if possible. The assessment of diagnostic tools is for the examiner not often possible due to the lack of evidence. Rhinosurgical approaches are often described in study reports; however, they lack the standard prospective randomized long-term study design required nowadays and can only be evaluated with caution in the literature.

Acute Rhinosinusitis in Children

Acute rhinosinusitis in children is a common disorder that is characterized by some or all of the following symptoms: fever, rhinorrhea, nasal congestion, cough, postnasal drainage, and facial pain/headache. It often starts as an upper respiratory tract infection that is complicated by a bacterial infection in which the symptoms worsen, persist, or are particularly severe. The accurate diagnosis of acute rhinosinusitis is challenging because of the overlap of symptoms with other common diseases, heavy reliance on subjective reporting of symptoms by the parents, and difficulties related to the physical examination of the child. Antibiotics are the mainstay of treatment. There is no strong evidence for the use of ancillary therapy. Orbital and intracranial complications may occur and are best treated early and aggressively. This article reviews the diagnosis, pathophysiology, bacteriology, treatment, and complications of acute rhinosinusitis in children.

Nasal decongestants in complex treatment of acute rhinosinusitis in children

Nasal decongestants in complex treatment of acute rhinosinusitis in children